Thiazolidinediones: A new class of antidiabetic drugs

Diabetic Medicine

Volumn 16, Issue 3, 1999, Pages 179-192

  Day, Caroline ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Insulin action enhancers; Peroxisome proliferator activated receptor ; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADD 4833; ANTIDIABETIC AGENT; CIGLITAZONE; DARGLITAZONE; ENGLITAZONE; FATTY ACID; GLUCOSE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG;

DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; CARBOHYDRATE METABOLISM; CHROMANS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; THIAZOLES;

EID: 0032727659     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00023.x     Document Type: Review

References (140)

1. 1 Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-1245.
2. 2 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
3. 3 Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
4. 4 Chaisson J-L, Josse RG, Hunt JA. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Int Med 1994; 121: 928-935.
5. 5 Coniffe RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154: 2442-2448.
6. 6 Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
7. 7 Galloway JA. Treatment of NIDDM with insulin agonists and substitutes. Diabetes Care 1990; 13: 1209-1239.
8. 8 Ohkubo Y, Kishikawa H, Ariki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomised prospective 6-year study. Diab Res Clin Pract 1995; 28: 103-117.
9. 9 Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990; 13 (Suppl 3): 37-41.
10. 10 DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-549.
11. 11 Panzram G. Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123-131.
12. 12 Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-1685.
13. 13 Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-1217.
14. 14 Keen H. Diabetes in the United Kingdom - 1996. London: British Diabetic Association, 1995; 1-48.
15. 15 UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
16. 16 Marks L. Counting the Cost: the Real Impact of Non-Insulin-Dependent Diabetes. King's Fund Policy Institute. London: British Diabetic Association, 1996; 1-48.
17. 17 Fujita T, Sugiyama Y, Taketomi S, Shoda T, Kawamatsu Y, Iwatsuka H et al. Reduction of insulin resistance in obese and/or diabetic animals by 3[-4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3870, U63287, ciglitazone), a new antidiabetic agent. Diabetes 1983; 32: 804-810.
18. 18 Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of a new and antidiabetic agent, CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1588.
19. 19 Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arz-Forsch/Drug Res 1990; 40: 156-162.
20. 20 Oakes ND, Kennedy CJ, Jenkins AB, Laybulf DR, Chrisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-1210.
21. 21 Chaiken RL, Eckert-Norton M, Pasmantier R, Boden G, Ryan I, Gelfand RA et al. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 1995; 38: 1307-1312.
22. 22 Chang AY, Wyse BM, Gilchrist BJ. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and - +/? mice. Diabetes 1983; 32: 839-845.
23. 23 Chang AY, Gilchrist BJ, Wyse BM. Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in the C57BL/6J-ob/ob and - +/? mice. Diabetologia 1983; 25: 514-520.
24. 24 Chang AY, Wyse BM, Gilchrist BJ, Diani AR. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 1983; 32: 830-838.
25. 25 Diani AR, Peterson T, Sawada GA, Wyse BM, Gilchrist BJ, Hearron AE et al. Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db mice. Diabetologia 1984; 27: 225-234.
26. 26 FujiwaraT, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T et al. Characterisation of CS-045, A new antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991; 40: 1213-1218.
27. 27 Fujiwara T, Okuno A, Yoshioka S, Hirokoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995; 44: 486-490.
28. 28 Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda II. Studies on antidiabetic agents. Synthesis and hypoglycaemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arz-Forsch/Drug Res 1990; 40: 37-42.
29. 29 Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF et al. Actions of a novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 1990; 39: 1218-1227.
30. 30 Stevenson RW, Gibbs EM, Kreutter DK, McPherson RK, Clark DA, Hulin B et al. The thiazolidinedione drug series. In The Diabetes Annual 9, Marshall SM, Home PD, Rizza RA (eds). Amsterdam: Elsevier Science, 1995; 175-191.
31. 31 Bowen L, Stein PP, Stevenson R, Schulman GI. The effect of CP 68,722, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 1991; 40: 1025-1030.
32. 32 Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ et al. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 1995; 44: 1087-1092.
33. 33 Lee MK, Miles PDG, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994; 43: 1435-1439.
34. 34 Khoursheed M, Miles PDG, Gao KM, Mossa AR, Olefsky JM. Metabolic effects of troglitazone on fat induced insulin resistance in the rat. Metabolism 1995; 44: 1489-1494.
35. 35 O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism 1997; 46: 192-198.
36. 36 Matsuhisa M, Shi ZQ, Wan C, Lekas M, Rodgers CD, Giacca A et al. The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs. Diabetes 1997; 46: 224-231.
37. 37 Colca JR, Morton DR Antihyperglycaemic thiazolidinediones: ciglitazone and its analogues. In Bailey CJ, Flatt PR eds. New Antidiabetic Drugs. London: Smith-Gordon, 1990; 255-261.
38. 38 Lee MK, Olefsky JM. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 1995; 44: 1166-1169.
39. 39 Inoue Y, Tanigawa K, Nakamura S, Gang X, Kawaguchi, Kato Y, Tamura K. Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats. Diabetes Res Clin Prac 1995; 27: 19-26.
40. 40 Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K et al. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997; 46: 981-983.
41. 41 Sugiyama Y, Shimura Y, Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arz Forsch/ Drug Res 1990; 40: 436-440.
42. 42 Burant CF, Screenan S, Hirano K, Tai TAC, Lohmiller J, Lukens J et al. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100: 2900-2908.
43. 43 Yoshioka S, Nishimo H, Shiraki T, Ikeda K, Koike H, Okuno A et al. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993; 42: 75-80.
44. 44 Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D et al. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible invovlement of leptin and hypothalamic neuropeptide Y. Brit J Pharmacol 1997; 122: 1405-1410.
45. 45 De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor. J Clin Invest 1996; 98: 1004-1009.
46. 46 Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuersterin BG, Kurtz TW. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 1993; 21: 1020-1023.
47. 47 Kemnitz JW, Elson DF, Roecher EB, Baum ST, Bergman RN, Meglasson M. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin and lipid levels, and lowers blood pressure in obese, insulin resistant rhesus monkeys. Diabetes 1994; 43: 204-211.
48. 48 Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension 1996; 28: 219-223.
49. 49 Kotchen TA, Zhang HY, Reddy S, Hoffman RG. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 1996; 270: R660-R666.
50. 2+ currents and not endothelial nitric oxide production. Diabetes 1997; 46: 659-664.
51. 51 Katayama S, Abe M, Kashiwabara H, Kosegawa I, Ishii J. Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance. Hypertension 1994; 23: 1071-1074.
52. 52 Kawaguchi M, Taniga wa K, Kato Y. A study of effect of CS-O45, a new antidiabetic drug on hypertension in spontaneously hypertensive rat. Endocrine J 1995; 42: 557-561.
53. 53 Peuler JD, Phare SM, Iannucci AR, Hoderek MJ. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle proliferation. Am J Hypertens 1996; 9: 188-192.
54. 54 Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
55. 55 Keller H, Dreyer C, Medin J, Mafoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993; 90: 2160-2164.
56. 56 Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: A nuclear receptor signalling pathway in lipid physiology. Ann Rev Cell Dev Biol 1996; 12: 353-363.
57. 57 Pfahl M, Chytil F. Regulation of metabolism by retinoic acid and its nuclear receptors. Annu Rev Nutr 1996; 16: 257-283.
58. 58 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)*. J Biol Chem 1995; 270: 12593-12956.
59. 59 Lambe KG, Tugwood JD. A human peroxisome proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 1996; 239: 1-7.
60. 60 Hallakon S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthould M-F et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393-1399.
61. 61 Kletzien R, Clarke S, Ulrich R. Enhancement of adipocyte differentiation by an insulin sensitizing agent. Mol Pharmacol 1992; 41: 393-398.
62. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83: 803-812.
63. 63 Hu F., Tontonoz P, Spiegelman BM. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/ FPBα. Proc Natl Acad Sei USA 1995; 92: 9856-9860.
64. 64 Teboul L, Gaillard D, Staccini L, Indera H, Amri EZ, Grimaldi PA. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J Biol Chem 1995; 270: 28183-28187.
65. 65 Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA et al. Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Molec Pharmacol 1996; 50: 1087-1094.
66. 66 Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders I. et al. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
67. 67 Lefebvre A-M, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47: 98-102.
68. 68 Wilson TM, Cobb JE, Cowan DJ, Weithe RW, Correa ID et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668.
69. 69 Okuno A, Ikeda K, Shiota M, Fujiwara T, Yoshioka S, Sugano T et al. Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb. Metabolism 1997; 46: 716-712.
70. 70 Furnsinn C, Neschen S, Noe C, Bisschop M, Roden M, Vogl C et al. Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro. Brit J Pharmacol 1997; 122: 1367-1374.
71. 71 Blackmore PF, McPherson RK, Stevenson RW. Actions of the novel antidiabetic agent englitazone in rat hepatocytes. Metabolism 1993; 42: 1583-1587.
72. 72 Ciraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990; 39: 1056-1062.
73. 73 Kreutler DK, Andrews K, Gibbs E, Hutson NJ, Stevenson RW. Insulin-like activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes. Diabetes 1990; 39: 414-419.
74. 74 Ciraldi TP, Huber-Knudsen K, Hickman M, Olefsky J. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 1995; 44: 976-982.
75. 75 Bahr M, Spelleken M, Bock M, von Holtey, Kiehn R, Eckel J. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia 1996; 39: 766-774.
76. 76 Kobayashi M, Iwanishi M, Egawa K, Shigeta Y. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992; 41: 476-483.
77. 77 Zhang B, Szalkowski D, Diaz E, Haves N, Smith R, Berger J. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedionde-derived antidiabetic agents in chinese hamster ovary cells expressing human insulin receptors and L6 myotubules. J Biol Chem 1994; 269: 25735-25741.
78. 78 Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 1994; 43: 447-453.
79. 79 Maegawa H, Ide R, Hasegawa M, Ugi S, Egawa K, Iwanishi M et al. Thiazolidinedione derivatives ameliorate high glucose-induced insulin resistance via normalization of protein-tyrosine phosphatase activities. J Biol Chem 1995; 270: 7724-7730.
80. 80 Storlien LH, Baur LA, Kriketos AD, Pan DA, Cooney GJ, Jenkins AB et al. Dietary fat and insulin action. Diabetologia 1996;39:621-631.
81. 81 Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Mauggeo M, Persson B et al. Trogltitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
82. 82 Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-1078.
83. 83 Weinstein SP, Holand A, O'Boyle E, Haber RS. Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism 1993; 42: 1365-1369.
84. 84 Hofmann C, Lorenz K, Colca JR. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991; 129: 1915-1925.
85. 85 Murase K, Odaka H, Suzuki M, Tayuki N, Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 1998; 41: 257-264.
86. 86 Miles PDG, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46: 1678-1683.
87. 87 Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha (TKF-α): A potential new insulin-sensitizing mechanism for the thiazolidinediones. Diabetes 1998; 47: 691-695.
88. 88 Kallen GB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Nat Acad Sci 1996; 93: 5793-5796.
89. 89 Nolan JJ, Olefsky JM, Nyce MR, Considine RV, Caro JF. Effects of troglitazone on leptin production. Studies in vitro in human subjects. Diabetes 1996; 45: 1276-1278.
90. 90 Iwanishi M, Egawa K, Ohara H, Kobayashi M. New oral agent to increase insulin sensitivity by activating kinase activity of insulin receptors. Diabetes 1990; 39 (Suppl 119A).
91. 91 Iwanishi M, Kobayashi M. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism 1993; 42: 1017-1021.
92. 92 Tontonez P, Singer S, Forman BM, Sharraf P, Fletcher JA, Fletcher CDM et al. Terminal differentiations of human liposarcoma cells induced by ligands forperoxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Nat Acad Sci USA 1997; 94: 237-241.
93. 93 Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
94. 94 Troglitazone Package Insert. Warner-Lambert Co., USA. December 1997.
95. 95 Petrides AS. Liver disease and diabetes mellitus. Diabetes Rev 1994; 2: 2-18.
96. 96 Williams GD, Deldar A, Jordan WH, Gries C, Long CG, Dimarch RD. Subchronic toxicity of the thiazolodinedione Tanabe-174 (LY282449), in the rat and dog. Diabetes 1993; 42: 186A.
97. 97 Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effect of combination therapy of troglitazone in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Med 1996; 13: 365-370.
98. 98 Ghazzi MM, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-439.
99. 99 Ogihara T, Rakugi H, Ikegami H, Mikama H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypetensives. Am J Hypertension 1995; 8: 316-320.
100. 100 Kuzuya T, Iwamoto Y, Kosaka K. A pilot clinical trial of a new oral hypoglycaemic agent CS-045 in patients with non-insulin-dependent diabetes mellitus. Diab Res Clin Pract 1991; 11: 147-154.
101. 101 Suter SL, Nolan JJ, Wallace P, Gumbiner B. Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
102. 102 Mimura K, Umeda F, Hiramatsu S. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med 1994; 11: 685-691.
103. 103 Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA et al. Metabolic effects of troglitazone on monotherapy in type 2 diabetes mellitus. Ann Int Med 1998; 128: 176-185.
104. 104 Hansen AP. Effects of troglitazone, a thiazolidinedione, in elderly non-insulin dependent diabetic patients. Diabetologia 1995; 38: A199.
105. 105 Valiquett T, Huang S, Whitcomb R. Effects of troglitazone in patients with NIDDM: a 6-month multicentre study. Diabetes 1997; 46 (Suppl 43A).
106. 106 Schaeffer EJ, Fava SL, Jenner JL. Lipoportein (a) levels and risk of coronary heart disease in men: the Lipid Research Coronary Primary Prevention Trial. JAMA 1994; 271: 999-1003.
107. 107 Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. Increases of lipoprotein (a) with troglitazone. Lancet 1997; 350: 1748-1749.
108. 108 Nagasaka Y, Kaku K, Nakamura K, Kaneko T. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma lipoproteins in vitro. Biochem Pharmacol 1995; 50: 1109-1111.
109. 109 Cominacini L, Young MMR, Capriati A, Garbin U, Fratta Pasini A, Campagnola M et al. Trogltiazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia 1997; 40: 1211-1218.
110. 110 Correa JCN, Hilsted J, Eckland D, Lettis S, Starkie M, Young M. Investigations of twice or three times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non-insulin dependent diabetes mellitus. Eur J Clin Res 1997; 9: 151-165.
111. 111 Eckland DJA, Frith L, Starkie M, Alderton C. Troglitazone improves albuminuria in Type 2 diabetic patients. Diabetologia 1997; 40: A312.
112. 112 Glazo Wellcome on file. Cited in Romozin (troglitazone) product monograph. Glaxo Wellcome, Sankyo Pharma UK Ltd.
113. 113 Nolan JJ, Ludvik B, Beardren P, Joyce A, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
114. 114 Antonucci T, McLain R, Whitcomb R, Lockwood D. Impaired glucose tolerance is normalised by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20: 188-193.
115. 115 Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield R et al. Troglitazone improves steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116.
116. 116 Ghazzi M, Radke-Mitchell, Venable T, Whitcomb R. Troglitazone improves glycemic control in patients with type 2 diabetes who are not optimally controlled on sulfonylurea. 1997; 46 (Suppl 44A).
117. 117 Buysschaert M, Rayman G, Bobbioni E. Troglitazone improves glycaemic control in patients on sulphonylureas alone. Diabetologia 1997; 40: A313.
118. 118 Foot EA, Patel J, Williams ZV, Eckland DJA. Improved metabolic control by addition of troglitazone to glibenclaminde therapy in non-insulin dependent diabetics. Diabetologia 1995; 38: A44.
119. 119 Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton B et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
120. 120 Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakuras, Inooka G. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14: 1083-1086.
121. 121 Schwartz S, Raskin P, Fonesca V, Graveline JF. Efficiacy of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338: 861-866.
122. 122 Gumbiner B, Buse J, Mathias N, Nelson D, Faja B, Whitcomb R. A double-blind, placebo-controlled, 26-week, multicenter study of troglitazone (CI-991) in patients with type II diabetes mellitus requiring insulin. 1997. Endocrine Society Abstracts, Proceedings of 79th Endocrine Society Congress.
123. 123 Shargill NS, Tatoyan A, Fulushima M, Antwi D, Bray GA, Chan TM. Effect of ciglitazone on glucose uptake and insulin sensitivity in skeletal muscle of the obese (ob/ob) mouse: distinct insulin and glucocorticoid effects. Metabolism 1986; 35: 64-70.
124. 124 Bolton GC, Keogh JP, East PD, Hollis FJ, Shore AD. The fate of a thiazolidinedione antidiabetic agent in rat and dog. Xenobiotica 1996; 26: 627-636.
125. 125 Miller E, Patel J, Reichek N, Granett J. BRL 49653 (a thiazolidinedione) is well tolerated and has no effect on LV mass following 12 weeks treatment in NIDDM patients. Diabetes 1997; 46 (Suppl 377A).
126. 126 Patel J, Miller E, Hu J, Granett J. BRL 49653 (a thiazolidinedione) improves glycemic control in NIDDM patients. Diabetes 1997; 46 (Suppl 150A0):
127. 127 Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K et al. Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 1995; 38: 24-30.
128. 128 Scrip. Troglitazone fall-out continues. Scrip 1997; December No. 2292: 20-21.
129. 129 Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern. N Engl J Med 1998; 338: 908-909.
130. 130 Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-917.
131. 131 Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 36-38.
132. 132 Neuschwander Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ et al. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 1998; 129: 38-41.
133. 133 Adams MD, Raman P, Judd RL. Comparative effects of englitazone and glyburide on gluconeogenesis and glycolysis in the isolated perfused rat liver. Biochem Pharmacol 1998; 55: 1915-1920.
134. 134 Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-537.
135. 135 Berkowitz R, Peters R, Kjos SL, Goico J, Marraquin A, Dunn ME et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 1996; 45: 1572-1579.
136. 136 Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
137. 137 Sigmund WR. Important Drug Warning - Dear Healthcare Professional. Parke Davis, USA, 23 July 1998.
138. 138 Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med 1998; 4: 1046-1052.
139. Min/+ mice. Nature Med 1998; 4: 1053-1057.
140. 140 Saez E, Tontonez P, Nelson MC, Alvarez JGA, Ming TU, Baird SM et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med 1998; 4: 1058-1061.